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ABSTRACT 
 
Serotonergic transmission is considered relevant in the pathophysiology and the 
treatment of schizophrenia. Tryptophan hydroxylase (TPH) is the rate limiting enzyme 
in the biosynthesis of serotonin. While the TPH1 gene has been found to be 
associated with schizophrenia, studies focussing on TPH2 variants did not yield 
conclusive results for schizophrenia or the response to antipsychotic medication. We 
analyzed eleven TPH2 SNPs in two case-control samples consisting of 4,453 
individuals in total. Six SNPs were selected because of their potential functional 
relevance (rs4570625, rs11178997, rs11178998, rs7954758, rs7305115, and, 
rs4290270) and were supported by another 5 tagging SNPs selected based on 
HapMap LD information. In the discovery sample (1,476 individuals), we observed a 
significant association with schizophrenia for rs10784941 (p=0.009, OR minor G-
allele 0.82 [0.71-0.95]) and rs4565946 (p=0.011, OR minor T-allele 0.83 [0.71-0.96]). 
Association was also observed with a common rs4570625-rs4565946 haplotype (OR 
G-C haplotype 1.20 [1.02-1.40]; p=0.0046). Single-marker associations could not be 
replicated in the replication sample consisting of 2,977 individuals, but there was a 
strong trend regarding the rs4570625-rs4565946 G-C haplotype (OR 1.10 [0.98-
1.24]; p(one-sided test)=0.054). In smaller subsamples, the rare rs4570625-
rs4565946 T-T haplotype was associated with reduced processing speed (n=193, 
p=.004) and sensorimotor gating (n=68, p=.006) of schizophrenia patients. TPH2 
variants and the rs4570625-rs4565946 G-C haplotype did not influence the beneficial 
response to antipsychotic drugs (n=210) after four weeks of treatment administering 
the Positive and Negative Syndrome Scale of Schizophrenia (PANSS). We also 
investigated the association of the SNPs to treatment response, but did not get 
significant results. In sum, our results argue for only a minor role of TPH2 in 
schizophrenia.  
 
 
Keywords: TPH2, schizophrenia, association study, response antipsychotics, 
cognition, PPI 
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1. Introduction 
 
Serotonergic transmission is considered relevant in the pathophysiology (Abi-
Dargham et al., 1997; Kishi et al., 2009) and the treatment of schizophrenia. 
Especially the serotonin receptor genes HTR1A and HTR2A play an important role in 
the pharmacogenetic response to antipsychotic treatment (Arranz et al., 1996; Arranz 
& de Leon, 2007; Mössner et al., 2009; Reynolds et al., 2006; Wang et al., 2008). 
Although many 5-HT receptor subtypes mediate the serotonergic transmission 
(Mössner et al., 2006a), the availability of serotonin also depends on its biosynthesis 
which is initiated by tryptophan hydroxylase (TPH). Serotonin is produced by 
generating 5-hydroxytryptophan out of tryptophan and the downstream 
decarboxylation using aromatic amino acid decarboxylase (Walther & Bader, 2003). 
Therefore TPH is the rate limiting enzyme in the biosynthesis of serotonin (Marziniak 
et al., 2009). Two TPH isoforms have been discovered in humans. Until recently, only 
one isoform (TPH1) was considered to be responsible for the 5-HT synthesis in the 
brain and in the periphery. In 2003, studies examining TPH knockout mice showed 
that serotonin levels were normal in most brain regions whereas serotonin was 
greatly diminished in the periphery (Walther & Bader, 2003; Walther et al., 2003). A 
second isoform (TPH2) was found, which has 71% amino acid identity with the 
isoform TPH1 (Walther & Bader, 2003). Many studies examining the expression of 
TPH1 and TPH2 strengthen the duality hypothesis saying that TPH1 is responsible 
for the periphery and TPH2 for the central nervous system respectively (Patel et al., 
2004; Walther & Bader, 2003; Zill et al., 2009). 
Postmortem brain analysis, cerebrospinal fluid studies, and pharmacological 
challenges suggest an impaired serotonin functioning in the cortex of patients with 
schizophrenia (Abi-Dargham et al., 1997). Furthermore 5-HT receptors might play a 
role in the predominant therapy response to antipsychotics (Meltzer et al., 2003). The 
TPH1 gene has been found to be associated with schizophrenia (Li & He, 2006; 
Saetre et al., 2009; Zaboli et al., 2006). The TPH1 isoform in mouse brain stem is 
expressed 150 times lower than TPH2 and recent studies suggest that TPH2, which 
is mainly expressed in the brain, is more relevant in the pathophysiology of 
psychiatric disorders. But until now studies investigating the association of TPH2 
variants with schizophrenia or the response to antipsychotic medication in 
dependence from TPH2 genotypes did not yield conclusive results. De Luca et al. 
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(2005) compared healthy controls with schizophrenia patients and found that 
schizophrenic individuals only showed a trend towards increased TPH2 mRNA levels 
compared to controls (De Luca et al., 2005). But the authors themselves remarked 
that the power of this analysis was very small with 0.18. In Japanese patients as well 
as in Malay patients no association was found between two variants and one variant 
of the TPH2 gene respectively, and schizophrenia (Higashi et al., 2007; Tee et al., 
2010). In another association study among Japanese patients neither one of the 15 
analyzed TPH2 variants nor their haplotypes were significantly associated with 
schizophrenia (Shiroiwa et al., 2011). In a fourth association analysis in a Korean 
sample none of the six investigated TPH2 variants (rs4570625, rs10748185, 
rs11179027, rs1386498, rs4469933, and rs17110747) were associated with 
schizophrenia or with the improvement of positive or negative symptomatology 
measured with the PANSS (Serretti et al., 2011). Zhang et al. 2011 (2011) did also 
not find an association of three TPH2 variants with schizophrenia in a Chinese 
sample. It is noteworthy that the allelic distribution of genetic variants differs with the 
ethnicity of the analyzed sample.  
 
Since four out of five association analyses were performed with Asian patients, a 
systematic investigation of TPH2 in Caucasian populations is clearly missing. Despite 
the missing evidence for association, such a study is, nevertheless, of interest due to, 
first, the biological plausibility for the association of TPH2 gene with the 
pathophysiology of schizophrenia and, secondly, the results that serotonin 
functioning in the cortex of patients with schizophrenia is impaired (Abi-Dargham et 
al., 1997). Therefore, we set out to conduct an extensive study focussing on TPH2, 
including association analysis between genetic variants and schizophrenia, analysis 
of promising endophenotypes and analysis of response  to psychotic therapy. In 
more detail, in a pilot study with a sample consisting of 788 schizophrenia patients 
and 688 healthy controls, we investigated 11 SNP markers and their haplotypes. We 
tried to replicate our finding in an independent replication sample consisting of 943 
schizophrenia patients and 2034 healthy controls. Since previous studies detected 
hints of association with schizophrenia endophenotypes (Zhang et al. 2011; Serretti 
et al., 2011), we enlarged the spectrum of our analysis to the established 
schizophrenia endophenotypes sensorimotor gating (Gottesman & Gould, 2003; 
Quednow et al., 2008a) and cognitive functioning. In order to complete the picture 
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and to investigate a potential link of our findings to therapy, we also investigated 
response on psychotropic medication. The analysis of the endophenotypes and drug 
response were carried out in three subsamples and focussed on a haplotype 
highlighted by our association study.  
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2. Material and methods 
 
2.1. Participants: Association study 
 
Schizophrenia inpatients were recruited from the Departments of Psychiatry and 
Psychotherapy at the Universities of Bonn, Düsseldorf, Munich, and the Central 
Institute of Mental Health in Mannheim. Schizophrenia was diagnosed according to 
the ICD-10 criteria for schizophrenia using structured interviews (DSM-IV, SKID). The 
healthy control subjects were identified via local city address registers and public 
notices and were all screened for the absence of psychiatric disorders by case 
history questionnaires. All patients and controls were of German Caucasian origin.  
The discovery sample consisted of 788 schizophrenia patients (470 males), who 
had an average age of 34.2 years, and 688 controls (326 males), who had an 
average age of 38.9 years. All patients and controls gave written informed consent to 
participate in the study. The study was approved by the appropriate ethics 
committees. All subsamples of schizophrenia patients described below were included 
in this discovery sample, see also table 1 for sample characteristics. 
The replication study consisted of 943 schizophrenia inpatients and 2034 healthy 
controls. The 943 schizophrenia patients (592 males) had an average age of 37.8 
years, while the 2034 controls (995 males) had an average age of 50.8 years. 
 
2.2. Participants and methods: Cognitive functioning and sensorimotor gating 
 
A subset of 193 schizophrenia patients (mean age of 36.4 years, 109 males), the 
NP (neuropsychological response) sample,  was assessed with a cognitive test 
battery as described in our previous study (Mössner et al., 2008). In short, five 
frequently used neuropsychological tests were assessed. Dependent measures and 
the corresponding tests were (1) the sensitivity score d’ of the Continuous 
Performance Test (CPT-IP) (Cornblatt et al., 1988), (2) the number of correctly coded 
symbols within the digit-symbol-substitution-task (DSST) (Wechsler, 1997), (3) free 
delayed recall (30 min) as measured by the Rey Auditory Verbal Learning Test 
(RAVLT) (Helmstaedter et al., 2001), (4) time to finish part B of the Trail-Making-Test 
(TMT) (Reitan & Wolfson, 1993), and (5) words produced in a lexical fluency task 
within 1 min (letters S/A/B/N) (Benton & Hamsher, 1989). The neuropsychological 
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assessments were done by trained and experienced psychologist or study nurses 
blind for genotype. All patients who underwent neuropsychological testing were 
screened for the absence of neurological disturbances and mental retardation. In 
order to minimize psychopharmacological effects, all assessments were done when 
the patients were on stable medication. In a second subset (ASR / PPI sample, table 
1) of 68 schizophrenia patients (mean age of 34.8 years, 46 males) exclusively 
recruited in the Department of Psychiatry and Psychotherapy, University of Bonn, 
sensorimotor gating (prepulse inhibition, PPI), startle response and habituation of the 
acoustic startle response (ASR) was recorded and analyzed as described in detail in 
our previous work (Quednow et al., 2006; Quednow et al., 2008b; Quednow et al., 
2010). From the ASR / PPI sample, 14 patients were unmedicated, 12 patients 
received first-generation antipsychotics, and 44 were treated with second-generation 
antipsychotics. The treated individuals were under stable medication. There was no 
correlation between TPH2 haplotypes and medication type.  
 
 
2.3. Participants and methods: Psychopathology during antipsychotic therapy 
 
Pharmacogenetic analyses were performed in a further subsample of the initial 
case control sample. It consisted of 210 schizophrenia patients (131 male) with a 
mean age of 32.7 years. Thereof, 69 were enrolled in a multicentre, randomized, 
double-blind comparison of risperidone and haloperidol conducted at psychiatric 
university hospital centres in Germany within the framework of the German Research 
Network on Schizophrenia (Wölwer et al., 2003). Patients were randomly assigned to 
either risperidone or haloperidol treatment for four weeks (Gaebel et al., 2004; Möller 
et al., 2008). Risperidone or haloperidol was given at a dose of two milligram/day, up 
to a maximum of eight mg/day, if required. 32 patients were treated with haloperidol; 
37 with risperidone. The only additional psychotropic drugs permitted during the 
study were benzodiazepines. Exclusion criteria were: pregnancy, contraindication to 
neuroleptic treatment, mental retardation, organic brain disease, substance 
abuse/dependence, and suicidal behavior in previous history (Gaebel et al., 2004). 
141 schizophrenia patients were admitted to the Department of Psychiatry and 
Psychotherapy of the University of Bonn due to an exacerbation of psychotic 
symptoms and they were treated with atypical antipsychotics. The atypical 
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antipsychotics used included olanzapine (n=63), amisulpride (n=47), clozapine 
(n=18), quetiapine (n=19), risperidone (n=13), ziprasidone (n=10), aripiprazole (n=7), 
bifeprunox (n=3), and iloperidone (n=1). Treatment with more than one atypical 
antipsychotic resulted from insufficient clinical response or side-effects (n=46) while 
the majority of the patients were treated with only one drug (n=95). Some patients 
were treated with more than one atypical antipsychotic. In both studies schizophrenia 
was diagnosed according to the ICD-10 criteria for schizophrenia and assessments 
were performed by administering the Positive and Negative Syndrome Scale 
(PANSS) for Schizophrenia (Kay et al., 1987). PANSS was scored by trained 
psychologists blind for TPH2 genotype at the start of treatment, and at weeks one 
and four. All patients were of German Caucasian origin and gave written informed 
consent to participate in the study. Both studies were approved by the appropriate 
ethics committees. 
 
2.4. Genotyping and SNP Selection 
 
We investigated 11 SNPs in total, six of which were selected because of their 
potential functional relevance (rs4570625, rs11178997, rs11178998, rs7954758, 
rs7305115, and, rs429027). Another 5 SNPs (table 2) were selected as supporting 
tagging SNPs based on HapMap LD information (The International HapMap 
Consortium, 2007). In all participants, DNA for the genotyping was isolated either 
from EDTA anticoagulated blood or permanent cell cultures received after 
transforming the lymphocytes with Epstein-Barr virus. The isolation followed the 
QIAGEN protocol for the Blood & Cell Culture DNA Maxi Kit (QIAGEN, Hilden, 
Germany). PCR was performed using 12.5 ng of DNA. We used SNP Genotyping 
Assays provided by Applied Biosystems. The procedure followed the protocol for 
Taqman® SNP-Genotyping also supplied by Applied Biosystems with the use of 
Taqman Universal PCR MasterMix (provided by Applied Biosystems, Foster City, CA, 
USA). Each of the assays consists of the unlabeled forward and reverse primers and 
two reporters, that are dye-labeled with FAMTM and VIC® and are designed for allelic 
discrimination of specific SNPs. Both alleles were scored in a single well by 
measuring the fluorescence at the end of the PCR using a Tecan Ultra 384 reader 
(Tecan, Crailsheim, Germany). Excitation- and emission-wavelengths for the Fam 
labeled probes were 485 and 535 nm and for the Vic labeled probes 535 and 590 
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nm, respectively. All SNPs had a call rate of at last 95%, in both case and control 
groups. After adjustment for multiple comparisons, there were no significant 
deviations from Hardy-Weinberg equilibrium (HWE) in any of the groups. 
 
2.5. Data analysis 
 
The case-control toolbox of FAMHAP (Herold & Becker, 2009) was used to 
perform statistical analysis of the case-control data. For each SNP, we used 
Armitage’s trend test (ATT) (Armitage, 1955) to test for an association with 
schizophrenia. Maximum-likelihood haplotype frequencies were estimated with the 
Expectation-Maximization algorithm and significance of haplotype association was 
assessed with a likelihood ratio test. As suggested by Becker and Herold (2009), we 
systematically screened the whole gene and tested all 2-marker haplotypes for 
association. Adjustment for multiple testing was performed with Monte-Carlo 
simulations based on permutation of case-control status (Herold & Becker, 2009). 
The methods also account for the non-independence of the tests caused by linkage 
disequilibrium (LD) between SNPs (Herold & Becker, 2009). 
The TPH2 haplotype yielding a significant association with schizophrenia was 
then tested for their effect on electrophysiological and cognitive endophenotypes as 
well as drug treatment response. 
Cognitive data were analyzed by univariate ANOVA with TPH2 haplotype as 
independent variable and cognitive function as dependent variable. Within these 
analyses, age, gender, and pre-morbid verbal intelligence were controlled for. 
Analyses of covariance (ANCOVA) with sex, smoking, antipsychotic medication 
status, and age as covariates were used to analyze ASR parameters (Quednow et 
al., 2011; Quednow et al., 2008b; Quednow et al., 2010). 
The time course of the treatment response, stratified by haplotype groups, was 
assessed by repeated-measurements ANCOVA (Admission, week 1, week 4) 
whereby the TPH2 haplotype served as factor and the respective PANSS value at 
admission served as covariate. To test for the distribution of gender regarding the 
genotype groups in both samples we made use of Pearson chi-square-test. 
Differences between the haplotype groups concerning the age of the patients and 
PANSS values at admission were assessed by variance analysis. The level of 
significance was set at 0.05 (two-tailed). Statistical analyses were performed using 
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SPSS statistical package 15.0 (SPSS Corp., Chicago, Illinois, USA). LD analysis was 
performed using Haploview (Barrett et al., 2005). 
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3. Results  
 
3.1. Association of TPH2 with schizophrenia 
 
Table 2 gives an overview over the eleven TPH2 SNP variants investigated. The 
association results for the discovery study can be found in table 3. In the discovery 
sample, rs10784941 showed strongest evidence for association (p=0.009, OR minor 
allele 0.82 [0.71-0.95]). The result remained significant after MC-simulation based 
adjustment for multiple SNPs tested (p=0.048; 1,000,000 permutations). 
Furthermore, rs4565946, a SNP in strong LD (r²=0.86) with rs10784941 also showed 
evidence for association (p=0.011, OR T- allele 0.83 [0.71-0.96]). Fig 1 presents the 
LD plot created with Haploview. As shown the first eight TPH2 variants are within one 
block and variants 9,10 and 11 can be found in the second block. As suggested by 
us elsewhere (Becker & Herold, 2009), we compared case and control haplotype 
frequencies for all two-SNP haplotypes and also for haplotypes extending over a 
complete block. The most significant haplotype distribution was obtained for 
rs4570625 and rs4565946 (table 4). The G-C haplotype showed an odds ratio of 1.20 
[1.02-1.40] and an uncorrected p-value of 0.0046. In addition to the G-C haplotype, 
the rare T-T haplotype (frequency in cases 1.8%, in controls 0.3%) showed an odds 
ratio of 6.25 [2.14-18.23] and an unadjusted p-value of 1.96*10-7.  
Since the most promising association results were found in the first block of 
TPH2, we followed up the respective SNPs in an independent case-control sample. 
The respective association results can be found in table 5. None of the SNPs showed 
significant association with schizophrenia. In particular, neither association of 
rs10784941 (p=0.403, OR 1-allele 1.05 [0.94-1.17]) nor of rs4565946 (p=0.387, OR 
of T-allel 0.95 [0.85-1.06]) could be replicated. The common haplotype distribution of 
rs4570625 and rs4565946 in the replication sample can be found in table 6. The rare 
T-T haplotype was not present in the replication sample and, therefore, could not be 
investigated. When testing one sided the G-C haplotype showed a trend (p=0.054) 
that was consistent with the first study. The association failed to reach significance 
when tested two-sided (OR 1.10 [0.98-1.24]; p=0.108). Other combinations of SNPs 
did not show improved haplotype significance levels. 
 
3.2. Cognitive functioning and sensorimotor gating in dependence from TPH2 
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For the analysis of cognitive, PPI, and pharmacogenetic data, we stratified the 
schizophrenia patients according to the TPH2 haplotype, which was found to be 
associated with schizophrenia in the first case control association analysis. Patients 
were classified in either having (one or two times) or not having this particular 
haplotype. 
Cognitive functioning was not affected by the rs4570625-rs4565946 G-C 
haplotype in the schizophrenia patients (all p>.05). However, the rare T-T haplotype 
was significantly related with reduced processing speed as measured by the digit-
symbol-substitution-task (DSST). Thus carriers of this haplotype only processed 39.1 
items (SD=10.6) on average while non-carriers achieved an average score of 49.3 
items (SD=10.5) (F(1/188)=8.73, p=.004) controlling for age, gender, and pre-morbid 
verbal intelligence (figure 2). After correction for multiple testing, no effect was found 
for any of the remaining cognitive functions.  
Interestingly, in single ANCOVAs corrected for sex, smoking, antipsychotic 
medication status, and age, PPI was also significantly associated with the T-T 
haplotype and the G-T haplotype. Carriers of the T-T haplotype but also of the G-T 
haplotype displayed worse sensorimotor gating functions (table 7). After correction 
for multiple testing only the effect of the T-T haplotype remained significant. The 
startle amplitude and habituation was not associated with any of the investigated 
TPH2 SNPs. 
 
3.3. Psychopathology during antipsychotic therapy in dependence from TPH2  
 
The improvement of positive, negative, general psychopathology symptoms and 
the total PANSS score showed no significant effect, neither for the eleven TPH2 
variants (data not presented here) nor for the TPH2 rs4570625-rs4565946 G-C and 
T-T haplotype. There were no differences regarding age, gender, positive, negative, 
general psychopathology and total PANSS values at admission between the eleven 
TPH2 variants and the G-C haplotype for the overall sample used for the 
pharmacogenetic analysis. The time course of the treatment response (admission- 
week1- week 4) in dependence from TPH2 G-C haplotype is shown in table 8.  
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4. Discussion 
 
TPH2 has up to now been linked to psychiatric disorders like bipolar disorder (Lin 
et al., 2007), suicide (Zhou et al., 2005; Zill et al., 2004) and early onset obsessive 
compulsive disorder (Mössner et al., 2006b). Studies investigating the association of 
TPH2 variants with schizophrenia or the response to antipsychotic medication in 
dependence from TPH2 genotypes, have until now been rare. These results 
prompted us to investigate the association of TPH2 with schizophrenia and the 
influence of TPH2 variants on endophenotypes like cognition, prepulse inhibition and 
treatment response in schizophrenia. 
Association analysis of variants of the TPH2 gene and schizophrenia in two 
independent case-control samples yielded inconclusive results. In our discovery 
sample, single-marker analysis was significant after adjustment for multiple testing. In 
addition to that, we observed strong association of rs4570625-rs4565946 haplotypes 
with schizophrenia. Both the G-C haplotype, which was previously implicated as 
leading to increased susceptibility for Tourette syndrome (Mössner et al., 2007), and 
the rare T-T haplotype showed evidence for increased risked of schizophrenia. 
However, these results could not be replicated in our second sample. The rare T-T 
haplotype was not present in the second study although it comprised more 
individuals. One might speculate that haplotype is in LD with a rare variant that exists 
only in the location the individuals of the first study were recruited from. On the other 
hand, it is also possible that a small number of genotyping errors at one of the SNPs 
have led to an artifact. Such errors are typically not detectable by the application of 
QC criteria that focus on single SNPs (Steffens et al., 2010).  
Our replication sample was well-powered to detect an effect of the magnitude 
observed in the first study (rs10784941, OR 0.82[0.71-0.95]): computations with the 
Genetic Power Calculator (Purcell et al., 2003) yielded a power of 91.5% to replicate 
the finding. However, if one assumes an overestimation of the effect in the first study, 
and postulates an effect equal to the limit of the confidence interval (OR= 0.95), the 
power is only 17%. Indeed, the effect size of the G-allele in the replication sample is 
0.95 (please note that the minor allele of both studies do not coincide, since allele 
frequencies are close to 0.5) which would be consistent with a very small effect. In 
line with this, the second most frequent G-C haplotype, showed a trend that was 
consistent with the initial study. However, since it failed to reach significance, further 
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studies are needed to enlighten the role of the TPH2 rs4570625-rs4565946 G-C 
haplotype 
 
In a subsample with available cognitive endophenotypes we observed altered 
processing speed due to a TPH2 haplotype. Carriers of the schizophrenia associated 
rare rs4570625-rs4565946 T-T haplotype coded significantly less digit-symbol 
combinations compared to non-carriers. The level of performance reached at the 
digit-symbol-substitution-task (DSST) is a very promising endophenotype for 
schizophrenia. Patients score approximately one and a half standard deviation below 
healthy comparison subjects (Dickinson et al., 2007). A comparative twin study found 
adequate heritability of 68% of the DSST (Swan & Carmelli, 2002). TPH2, in 
particular the T-allele of the rs4570625, has been previously related to cognitive 
functions in healthy populations and ADHD patients as well (Baehne et al., 2009; 
Osinsky et al., 2009; Reuter et al., 2007; Strobel et al., 2007). Moreover, Reuter and 
colleagues (2008) showed significantly increased activation in carriers of the TT 
genotype of this variant in the frontal and motor cortex while performing a working 
memory task in the fMRI. This finding underlines the importance of TPH2 for complex 
cognitive functions of frontal and prefrontal cortical areas. In line with this DSST 
result, carriers of the T-T haplotype also displayed disrupted sensorimotor gating of 
the ASR, which is an established endophenotype of schizophrenia as well 
(Gottesman & Gould, 2003; Quednow et al., 2008a). We have previously shown that 
other variants from the serotonin system such as HT2A receptor SNPs affect 
sensorimotor gating likewise (Quednow et al., 2008b; Quednow et al., 2009). Thus, in 
future it would be of high interest to investigate gene-gene interactions of TPH2 and 
the HT2A receptor SNPs regarding sensorimotor gating but also with regard to the 
risk of schizophrenia. Interestingly, in single ANCOVAs corrected for sex, smoking, 
antipsychotic medication status, and age, PPI was also significantly associated with 
the T-T haplotype and the G-T haplotype, which is in line with the assumption that a 
PPI deficit represents an endophenotype of schizophrenia (Gottesman & Gould, 
2003; Quednow et al., 2008a). 
Pharmacogenetic analysis focussing on the eleven TPH2 variants and the 
relevant rs4570625-rs4565946 G-C haplotype in a smaller subsample of 210 patients 
did not show any association neither of the eleven variants (data not presented here) 
nor of the G-C and the T-T haplotype with response to antipsychotic medication after 
Schuhmacher, Becker et al. TPH2 and schizophrenia 
 
15
15
four weeks of treatment administering the PANSS. We are not able to estimate the 
long-term effect of the interaction between TPH2 haplotype and treatment outcome 
because of the short period of assessment. However, it has been shown for other 
variants that the pharmacogenetic influence on outcome is similar at 4 weeks and 2–
3 months (Mössner et al., 2009). Our findings did not confirm a major influence of 
TPH2 variants on treatment response to antipsychotics. Concerning the course of 
psychopathology in dependence from TPH2 Zhang et al. (2011) found an association 
of rs4570625 with the PANSS positive subscale. T/T carriers had higher positive 
symptom scores than G/G and G/T carriers (P=0.043 and 0.031, respectively). 
However, their results were not corrected for multiple testing and in contrast to the 
actual study their results were not based on repeated measurements. We could not 
find any association of the eleven TPH2 variants and TPH2 rs4570625-rs4565946 G-
C and T-T haplotype on PANSS scores at baseline and in the course of antipsychotic 
treatment.  
What are the limitations of our study? We have presented results from a two-
stage association analysis of TPH2 in a Caucasian population. Despite considerable 
sample size, we were not able to significantly replicate interesting findings from our 
discovery study. Even larger sample size would be required to replicate our initial 
finding if that was driven by some winner’s course. The common rs4570625-
rs4565946 G-C haplotype showed a trend in the second sample, but failed to reach 
significance. The strongly associated, rare rs4570625-rs4565946 T-T haplotype was 
absent in our replication study, recruited from a geographic region about 400 km 
away from the recruiting region of the initial study, but was also related to a cognitive 
(processing speed) and a electrophysiological (sensorimotor gating) endophenotype 
of schizophrenia in subsamples of the first study, thus, giving some support for a true 
finding. On the other hand, these results have to be treated with some caution since 
the respective subsamples were rather small in comparison to the association 
samples. We also have to emphasize that most patients of the sub-samples were 
under antipsychotic treatment which is known to have a potential impact on cognition 
(Quednow et al, 2006; Tandon, 2011). However, since all patients were under stable 
medication at the point of the analysis and since we adjusted for medication status in 
the statistical analysis, we believe that this potential influence on the results could be 
minimized. Finally, association with response to psychotic treatment could not be 
observed for any of the investigated SNPs or haplotypes. 
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In summary, the question of the relevance of TPH2 genetic variation for 
schizophrenia or schizophrenia endophenotypes could not be answered finally. Our 
findings reveal only a minor role of TPH2 haplotypes for schizophrenia.  
 
 
 
 
Acknowledgements 
 
This study was part of the German Research Network on Schizophrenia and was 
funded by the German Federal Ministry for Education and Research BMBF (grants 
01GI0501, 01GI0232, 01GI0234, 01GV0907, and NGFN+ MooDs PNM-01GS08146-
3), the German Research Foundation DFG (grants Wa 731/6 and Wa 731/4), and by 
the 7th framework programme of the European Union (ADAMS project, HEALTH-F4-
2009-242257). Dr. Quednow is supported by the Swiss National Science Foundation 
(Grant No. PP00P1_123516). We thank V. Guttenthaler and A. Petruschke for expert 
technical assistance. The authors thank all clinicians, psychiatrists, psychologists, 
and study nurses involved in the study. 
 
Conflict of interest:  
None declared.
Schuhmacher, Becker et al. TPH2 and schizophrenia 
 
17
17
References 
 
Abi-Dargham A, Laruelle M, Aghajanian GK, Charney D, Krystal J. The role of 
serotonin in the pathophysiology and treatment of schizophrenia. The Journal 
of Neuropsychiatry & Clinical Neurosciences 1997;9(1):1-17. 
Armitage P. Tests for linear trends in proportions and frequencies. Biometrics 
1955;11(3):375-386. 
Arranz MJ, Collier DA, Munro J, Sham P, Kirov G, Sodhi M, et al. Analysis of a 
structural polymorphism in the 5-HT2A receptor and clinical response to 
clozapine. Neuroscience Letters 1996;217(2-3):177-178. 
Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: 
a review of last decade of research. Molecular Psychiatry 2007;12(8):707-747. 
Baehne CG, Ehlis AC, Plichta MM, Conzelmann A, Pauli P, Jacob C, et al. Tph2 
gene variants modulate response control processes in adult ADHD patients 
and healthy individuals. Molecular Psychiatry 2009;14(11):1032-1039. 
Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and 
haplotype maps. Bioinformatics 2005;21(2):263-265. 
Becker T, Herold C. Joint analysis of tightly linked SNPs in screening step of 
genome-wide association studies leads to increased power. European Journal 
of Human Genetics 2009;17(8):1043-1049. 
Benton AL, Hamsher K. Multilingual aphasia examination. Iowa City Iowa: AJA 
Associates,1989. 
Cornblatt BA, Risch NJ, Faris G, Friedman D, Erlenmeyer-Kimling L. The Continuous 
Performance Test, identical pairs version (CPT-IP): I. New findings about 
sustained attention in normal families. Psychiatry Research 1988;26(2):223-
238. 
De Luca V, Likhodi O, Van Tol HH, Kennedy JL, Wong AH. Tryptophan hydroxylase 
2 gene expression and promoter polymorphisms in bipolar disorder and 
schizophrenia. Psychopharmacology (Berl) 2005;183(3):378-382. 
Dickinson D, Ramsey ME, Gold JM. Overlooking the obvious: a meta-analytic 
comparison of digit symbol coding tasks and other cognitive measures in 
schizophrenia. Archives of General Psychiatry 2007;64(5):532-542. 
Gaebel W, Moller HJ, Buchkremer G, Ohmann C, Riesbeck M, Wolwer W, et al. 
Pharmacological long-term treatment strategies in first episode schizophrenia-
-study design and preliminary results of an ongoing RCT within the German 
Research Network on Schizophrenia. European Archives of Psychiatry and 
Clinical Neuroscience 2004;254(2):129-140. 
Gottesman, II, Gould TD. The endophenotype concept in psychiatry: etymology and 
strategic intentions. The American Journal of Psychiatry 2003;160(4):636-645. 
Helmstaedter C, Lendt M, Lux S. Verbaler Lern- und Merkfähigkeitstest. Göttingen: 
Beltz, 2001. 
Herold C, Becker T. Genetic association analysis with FAMHAP: a major program 
update. Bioinformatics 2009;25(1):134-136. 
Higashi S, Ohnuma T, Shibata N, Higashi M, Matsubara Y, Arai H. No genetic 
association between tryptophan hydroxylase 2 gene polymorphisms and 
Japanese schizophrenia. Psychiatric Genetics 2007;17(2):123. 
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) 
for schizophrenia. Schizophrenia Bulletin 1987;13(2):261-276. 
Schuhmacher, Becker et al. TPH2 and schizophrenia 
 
18
18
Kishi T, Tsunoka T, Ikeda M, Kitajima T, Kawashima K, Okochi T, et al. Serotonin 1A 
receptor gene is associated with Japanese methamphetamine-induced 
psychosis patients. Neuropharmacology 2009; 
Li D, He L. Meta-analysis shows association between the tryptophan hydroxylase 
(TPH) gene and schizophrenia. Human Genetics 2006;120(1):22-30. 
Lin YM, Chao SC, Chen TM, Lai TJ, Chen JS, Sun HS. Association of functional 
polymorphisms of the human tryptophan hydroxylase 2 gene with risk for 
bipolar disorder in Han Chinese. Archives of General Psychiatry 
2007;64(9):1015-1024. 
Marziniak M, Kienzler C, Kuhlenbaumer G, Sommer C, Mossner R. Functional gene 
variants of the serotonin-synthesizing enzyme tryptophan hydroxylase 2 in 
migraine. Journal of Neural Transmission 2009;116(7):815-819. 
Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs 
to treat schizophrenia. Progress in Neuro-Psychopharmacology & Biological 
Psychiatry 2003;27(7):1159-1172. 
Möller HJ, Riedel M, Jager M, Wickelmaier F, Maier W, Kuhn KU, et al. Short-term 
treatment with risperidone or haloperidol in first-episode schizophrenia: 8-
week results of a randomized controlled trial within the German Research 
Network on Schizophrenia. The International Journal of 
Neuropsychopharmacology 2008;11(7):985-997. 
Mössner R, Freitag CM, Gutknecht L, Reif A, Tauber R, Franke P, et al. The novel 
brain-specific tryptophan hydroxylase-2 gene in panic disorder. Journal of 
Psychopharmacology 2006a;20(4):547-552. 
Mössner R, Muller-Vahl KR, Doring N, Stuhrmann M. Role of the novel tryptophan 
hydroxylase-2 gene in Tourette syndrome. Molecular Psychiatry 
2007;12(7):617-619. 
Mössner R, Schuhmacher A, Kuhn KU, Cvetanovska G, Rujescu D, Zill P, et al. 
Functional serotonin 1A receptor variant influences treatment response to 
atypical antipsychotics in schizophrenia. Pharmacogenetics and Genomics 
2009;19(1):91-94. 
Mössner R, Schuhmacher A, Schulze-Rauschenbach S, Kuhn KU, Rujescu D, 
Rietschel M, et al. Further evidence for a functional role of the glutamate 
receptor gene GRM3 in schizophrenia. European Neuropsychopharmacology 
2008;18(10):768-772. 
Mössner R, Walitza S, Geller F, Scherag A, Gutknecht L, Jacob C, et al. 
Transmission disequilibrium of polymorphic variants in the tryptophan 
hydroxylase-2 gene in children and adolescents with obsessive-compulsive 
disorder. The International Journal of Neuropsychopharmacology 
2006b;9(4):437-442. 
Osinsky R, Schmitz A, Alexander N, Kuepper Y, Kozyra E, Hennig J. TPH2 gene 
variation and conflict processing in a cognitive and an emotional Stroop task. 
Behavioural Brain Research 2009;198(2):404-410. 
Patel PD, Pontrello C, Burke S. Robust and tissue-specific expression of TPH2 
versus TPH1 in rat raphe and pineal gland. Biological Psychiatry 
2004;55(4):428-433. 
Quednow BB, Ettinger U, Mossner R, Rujescu D, Giegling I, Collier DA, et al. The 
schizophrenia risk allele C of the TCF4 rs9960767 polymorphism disrupts 
sensorimotor gating in schizophrenia spectrum and healthy volunteers. The 
Journal of Neuroscience 2011;31(18):6684-6691. 
Schuhmacher, Becker et al. TPH2 and schizophrenia 
 
19
19
Quednow BB, Frommann I, Berning J, Kuhn KU, Maier W, Wagner M. Impaired 
sensorimotor gating of the acoustic startle response in the prodrome of 
schizophrenia. Biological Psychiatry 2008a;64(9):766-773. 
Quednow BB, Kuhn KU, Beckmann K, Westheide J, Maier W, Wagner M. Attenuation 
of the prepulse inhibition of the acoustic startle response within and between 
sessions. Biological Psychology 2006;71(3):256-263. 
Quednow BB, Kuhn KU, Mossner R, Schwab SG, Schuhmacher A, Maier W, et al. 
Sensorimotor gating of schizophrenia patients is influenced by 5-HT2A 
receptor polymorphisms. Biological Psychiatry 2008b;64(5):434-437. 
Quednow BB, Schmechtig A, Ettinger U, Petrovsky N, Collier DA, Vollenweider FX, 
et al. Sensorimotor gating depends on polymorphisms of the serotonin-2A 
receptor and catechol-O-methyltransferase, but not on neuregulin-1 Arg38Gln 
genotype: a replication study. Biological Psychiatry 2009;66(6):614-620. 
Quednow BB, Wagner M, Mossner R, Maier W, Kuhn KU. Sensorimotor gating of 
schizophrenia patients depends on Catechol O-methyltransferase Val158Met 
polymorphism. Schizophrenia Bulletin 2010;36(2):341-346. 
Purcell S, Cherny SS, Sham PC. Genetic Power Calculator: design of linkage and 
association genetic mapping studies of complex traits. Bioinformatics 2003; 
19(1):149-150. 
Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery: 
Theory and Clinical Interpretation, 2nd Edition. Tucson, Arizona: 
Neuropsychology Press, 1993. 
Reuter M, Esslinger C, Montag C, Lis S, Gallhofer B, Kirsch P. A functional variant of 
the tryptophan hydroxylase 2 gene impacts working memory: a genetic 
imaging study. Biological Psychology 2008;79(1):111-117. 
Reuter M, Ott U, Vaitl D, Hennig J. Impaired executive control is associated with a 
variation in the promoter region of the tryptophan hydroxylase 2 gene. Journal 
of Cognitive Neuroscience 2007;19(3):401-408. 
Reynolds GP, Arranz B, Templeman LA, Fertuzinhos S, San L. Effect of 5-HT1A 
receptor gene polymorphism on negative and depressive symptom response 
to antipsychotic treatment of drug-naive psychotic patients. The American 
Journal of Psychiatry 2006;163(10):1826-1829. 
Saetre P, Lundmark P, Hansen T, Rasmussen HB, Djurovic S, Melle I, et al. The 
tryptophan hydroxylase 1 (TPH1) gene, schizophrenia susceptibility, and 
suicidal behavior: A multi-centre case-control study and meta-analysis. 
American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 
2009; 
Serretti A, Chiesa A, Porcelli S, Han C, Patkar AA, Lee SJ, et al. Influence of TPH2 
variants on diagnosis and response to treatment in patients with major 
depression, bipolar disorder and schizophrenia. Psychiatry Research 
2011;189(1):26-32. 
Shiroiwa K, Hishimoto A, Mouri K, Fukutake M, Supriyanto I, Nishiguchi N, et al. 
Common genetic variations in TPH1/TPH2 genes are not associated with 
schizophrenia in Japanese population. Neuroscience Letters 2011;472(3):194-
198. 
Steffens M, Becker T, Sander T, Fimmers R, Herold C, Holler DA, et al. Feasible and 
successful: genome-wide interaction analysis involving all 1.9 x 10(11) pair-
wise interaction tests. Human Heredity 2010;69(4):268-284. 
Strobel A, Dreisbach G, Muller J, Goschke T, Brocke B, Lesch KP. Genetic variation 
of serotonin function and cognitive control. Journal of Cognitive Neuroscience 
2007;19(12):1923-1931. 
Schuhmacher, Becker et al. TPH2 and schizophrenia 
 
20
20
Swan GE, Carmelli D. Evidence for genetic mediation of executive control: a study of 
aging male twins. The Journals of Gerontology, Series B: Psychological 
Sciences and Social Sciences 2002;57(2):P133-143. 
Tandon R. (2011) Antipsychotics in the treatment of Schizophrenia: an overview. The 
Journal of clinical psychiatry 72 Suppl 14-8. 
Tee SF, Chow TJ, Tang PY, Loh HC. Linkage of schizophrenia with TPH2 and 5-
HTR2A gene polymorphisms in the Malay population. Genetics and Molecular 
Research 2010;9(3):1274-1278. 
The International HapMap Consortium. A second generation human        haplotype 
map of over 3.1 million SNPs. Nature 2007;449(7164): 851-861. 
Walther DJ, Bader M. A unique central tryptophan hydroxylase isoform. Biochemical 
Pharmacology 2003;66(9):1673-1680. 
Walther DJ, Peter JU, Bashammakh S, Hortnagl H, Voits M, Fink H, et al. Synthesis 
of serotonin by a second tryptophan hydroxylase isoform. Science 
2003;299(5603):76. 
Wang L, Fang C, Zhang A, Du J, Yu L, Ma J, et al. The --1019 C/G polymorphism of 
the 5-HT(1)A receptor gene is associated with negative symptom response to 
risperidone treatment in schizophrenia patients. Journal of 
Psychopharmacology 2008;22(8):904-909. 
Wechsler D. Wechsler Adult Intelligence Scale. 3rd Edition. San Antonio, Texas: 
Psychological Corp, 1997. 
Wölwer W, Buchkremer G, Hafner H, Klosterkotter J, Maier W, Moller HJ, et al. 
German research network on schizophrenia-bridging the gap between 
research and care. European Archives of Psychiatry and Clinical 
Neuroscience 2003;253(6):321-329. 
Zaboli G, Jonsson EG, Gizatullin R, Asberg M, Leopardi R. Tryptophan hydroxylase-
1 gene variants associated with schizophrenia. Biological Psychiatry 
2006;60(6):563-569. 
Zhang C, Li Z, Shao Y, Xie B, Du Y, Fang Y, et al. Association study of tryptophan 
hydroxylase-2 gene in schizophrenia and its clinical features in Chinese Han 
population. Journal of Molecular Neuroscience 2011;43(3):406-411. 
Zhou Z, Roy A, Lipsky R, Kuchipudi K, Zhu G, Taubman J, et al. Haplotype-based 
linkage of tryptophan hydroxylase 2 to suicide attempt, major depression, and 
cerebrospinal fluid 5-hydroxyindoleacetic acid in 4 populations. Archives of 
General Psychiatry 2005;62(10):1109-1118. 
Zill P, Buttner A, Eisenmenger W, Moller HJ, Bondy B, Ackenheil M. Single 
nucleotide polymorphism and haplotype analysis of a novel tryptophan 
hydroxylase isoform (TPH2) gene in suicide victims. Biological Psychiatry 
2004;56(8):581-586. 
Zill P, Buttner A, Eisenmenger W, Muller J, Moller HJ, Bondy B. Predominant 
expression of tryptophan hydroxylase 1 mRNA in the pituitary: a postmortem 
study in human brain. Neuroscience 2009;159(4):1274-1282. 
 
 
 
Schuhmacher, Becker et al. TPH2 and schizophrenia 
 
21
21
Figure legend: 
 
Fig. 1: LD plot of the investigated TPH2 variants created with Haploview. 
 
Figure 2: Performance of schizophrenia patients carrying the rare TPH2 rs4570625-
rs4565946 T-T haplotype in the digit-symbol-substitution-task. Carriers of this 
haplotype only processed 39.1 items (SD = 10.6) on average while non-carriers 
achieved an average score of 49.3 items (SD = 10.5) (F = 8.73, df = 1/188, p = .004). 
 
 
 
Table 1: Description of TPH2 variants, amino acid change and localization on gene
rs number Nucleotide exchange Location in Gene Location on Chromosome 
rs4570625 T -703 G Promoter chr12:72331923
rs11178997 T -473 A Promoter chr12:72332153
rs11178998 A 90 G 5´UTR (Exon1) chr12:72332715
rs4341581 intronic (G/T) Intron 1 chr12:72335073
rs7954758 intronic (A/G) Intron 2 chr12:72335794
rs10784941 intronic (A/G) Intron 2 chr12:72336512
rs4565946 intronic (C/T) Intron 2 chr12:72336769
rs11179000 intronic (A/T) Intron 4 chr12:72338628
rs7305115 G 40237 A (Pro312Pro) Exon 7 chr12:72372862
rs4290270 A 83610 T (Ala375Ala) Exon 9 chr12:72416235
rs17110747 G 93329 A 3´UTR (Exon11) chr12:72425954
Note: the amino acid is also indicated, where applicable
Table(s)
Table 2: Association of TPH2 variants with schizophrenia in the discovery sample
rs number Minor/major allele p  value ATT
1
OR
2 
and confidence interval
cases controls
rs4570625 T/G 0.22 0.20 0.2340 1.12 [0.30-1.34]
rs11178997 A/T 0.07 0.06 0.3490 1.16 [0.85-1.57]
rs11178998 G/A 0.06 0.06 0.4360 1.13 [0.83-1.54]
rs4341581 G/T 0.04 0.04 0.8870 1.03 [0.71-1.49]
rs7954758 G/A 0.07 0.06 0.3430 1.16 [0.85-1.57]
rs10784941 G/A 0.47 0.52 0.0091 0.82 [0.71-0.95]
rs4565946 T/C 0.43 0.48 0.0106 0.83 [0.71-0.96]
rs11179000 T/A 0.24 0.21 0.0668 1.18 [0.99-1.40]
rs7305115 A/G 0.41 0.39 0.2040 1.10 [0.95-1.28]
rs4290270 A/T 0.36 0.35 0.5320 1.05 [0.90-1.22]
rs17110747 A/G 0.15 0.13 0.1800 1.16 [0.94-1.43]
1
 Armitage trend test
2
 Odds ratios are given for minor allele
 Minor allele frequencies
Table(s)
Haplotype Odds ratio and confidence interval p  value
Cases Controls
G C   0.364   0.323 1.20 [1.02-1.40] 0.0046100
G T   0.418   0.481 0.78 [0.67-0.90] 0.0002490
T C   0.200   0.194 1.04 [0.87-1.26] n.s.
1
T T   0.018   0.003 6.25 [2.14-18.23] 0.0000002
1
not significant: p -value > 0.2
Frequencies
Table 3: Haplotype frequencies and accociation results for haplotype rs4570625-
rs4565946 in the discovery sample
Table(s)
Table 4: Association of TPH2 variants with schizophrenia in the replication sample
rs number Minor/major allele p  value ATT
1
OR
2 
and confidence interval
cases controls
rs4570625 T/G 0.20 0.21 0.3710 0.94 [0.82-1.08]
rs11178997 A/T 0.06 0.07 0.2190 0.87 [0.69-1.09]
rs11178998 G/A 0.06 0.07 0.1400 0.84 [0.67-1.06]
rs4341581 G/T 0.04 0.04 0.9920 1.00 [0-75-1.32]
rs7954758 G/A 0.06 0.07 0.2710 0.88 [0.70-1.10]
rs10784941 A/G 0.48 0.49 0.4030 1.05 [0.94-1.17]
rs4565946 T/C 0.45 0.46 0.3870 0.95 [0.85-1.06]
1
 Armitage trend test
2
 Odds ratios are given for minor allele
 Minor allele frequencies
Table(s)
Haplotype Odds ratio and confidence interval p  value 
Cases Controls
G C   0.352   0.330 1.10 [0.98-1.24] 0.054
G T   0.445   0.457 0.95 [0.85-1.06] n.s.
1
T C   0.204   0.212 0.95 [0.83-1.09] n.s.
1
T T   0.000   0.000 - -
1
not significant: p-value > 0.2
Frequencies
Table 5: Haplotype frequencies and accociation results for haplotype rs4570625-
rs4565946 in thereplication sample
Table(s)
Haplotype p  value 1
Haplotype Other
G C (n=53) 44.5 (4.1) 28.0 (8.8) 0.097
G T (n=41) 34.8 (4.5) 52.8 (5.9) 0.020
T C (n=27) 34.2 (5.8) 46.6 (4.9) 0.113
T T (n=14) 22.3 (7.7) 47.1 (3.9) 0.006
PPI 
Table 6: Prepulse-Inhibition (PPI) values (means and 
standard errors of means in parentheses) for haplotype 
rs4570625-rs4565946 in 68 schizophrenia patients
1
 ANCOVA corrected for age, sex, smoking and antipsychotic 
medication
Table(s)
Positive and negative 
syndrome scale for  
Schizophrenia: PANSS
TPH2 Haplotype  
GC
Symptoms
at admission
Symptoms 
at week 1
Symptoms 
at week 4
p  Value
1
0x (n=83) 22.70 +- 6.69 16.40 +- 4.36 13.57 +-3.93 0.74
1x (n=100) 22.14 +- 4.72 16.54 +- 4.64 13.42 +- 3.95
2x (n=27) 21.30 +- 4.22 16.04 +- 4.86 13.04 +- 3.09
0x (n=83) 21.17 +- 5.13 18.59 +- 5.46 16.63 +- 3.78 0.71
1x (n=100) 20.87 +- 6.23 18.90 +- 6.36 16.52 +- 5.46
2x (n=27) 21.63 +- 5.69 19.22 +- 6.00 18.15 +- 4.61
0x (n=83) 42.76 +- 10.20 36.28 +- 8.55 32.63 +- 7.12 0.26
1x (n=100) 42.42 +- 9.80 36.32 +- 9.18 30.88 +- 7.82
2x (n=27) 42.00 +- 8.21 37.37 +- 10.14 32.96 +- 7.94
0x (n=83) 86.69 +- 18.39 71.10 +- 16.79 62.96 +- 13.43 0.41
1x (n=100) 85.63 +- 18.31 71.81 +- 17.97 61.00 +- 15.60
2x (n=27) 84.70 +- 16.52 72.67 +- 19. 46 64.00 +- 13.66
Symptoms are reported as mean and standard deviation
1
 p  value for repeated measurements analysis of variance (admission, week 1, week 4), independent variable: TPH2 
haplotype (stratified according to no haplotype or one or two times haplotype), covariate: respective PANSS value at 
admission
Positive symptoms 
Negative symptoms 
Table 7: Time course of treatment response on PANSS scales in 210 patients stratified by TPH2 haplotype 
rs4570625-rs4565946
General psychopathology
Total PANSS score 
Table(s)
Figure(s)
Figure(s)
